Bempegaldesleukin
Bempegaldesleukin is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target interleukin-2 receptor subunit beta.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 3 | 2 | — | — | — | 3 | |
| Squamous cell carcinoma of head and neck | D000077195 | 2 | 2 | — | — | — | 2 | ||
| Non-small-cell lung carcinoma | D002289 | 2 | 2 | — | — | — | 2 | ||
| Triple negative breast neoplasms | D064726 | 2 | 2 | — | — | — | 2 | ||
| Sarcoma | D012509 | 1 | 2 | — | — | — | 2 | ||
| Prostatic neoplasms | D011471 | C61 | 1 | 1 | — | — | — | 1 | |
| Urologic neoplasms | D014571 | C64-C68 | 1 | 1 | — | — | — | 1 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 1 |
| Leukemia | D007938 | C95 | 1 | 1 | — | — | — | 1 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
| Covid-19 | D000086382 | U07.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BEMPEGALDESLEUKIN |
| INN | bempegaldesleukin |
| Description | Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
|
| Classification | Protein |
| Drug class | interleukins: interleukin-2 analogues and derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1939126-74-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298058 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15140 |
| UNII ID | BNO1JG5MZC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL2RB
IL2RB
Organism
Homo sapiens
Gene name
IL2RB
Gene synonyms
IL15RB
NCBI Gene ID
Protein name
interleukin-2 receptor subunit beta
Protein synonyms
CD122, CD122 antigen, high affinity IL-2 receptor beta subunit, High affinity IL-2 receptor subunit beta, IL-2 receptor subunit beta, IL-2R subunit beta, IL-2RB, interleukin 15 receptor, beta, interleukin 2 receptor, beta, Interleukin-15 receptor subunit beta, p70-75, p75
Uniprot ID
Mouse ortholog
Il2rb (16185)
interleukin-2 receptor subunit beta (Q3TZT2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 298 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
150 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more